Antidepressive activity

Antidepressive activity refers to the physiological or clinical effect of a substance or intervention that alleviates the symptoms of clinical depression and related mood disorders. It is not a discrete molecular target, such as a specific protein, enzyme, or receptor, but rather a complex pharmacological outcome resulting from the modulation of various biological pathways (StatPearls, 2023; NIH MeSH). Historically, this activity was primarily associated with the 'monoamine hypothesis,' which suggests that depression is caused by a deficiency in neurotransmitters like serotonin, norepinephrine, or dopamine (Molecular Psychiatry, 2022). Modern research has expanded this definition to include the enhancement of neuroplasticity, synaptogenesis, and the regulation of the hypothalamic-pituitary-adrenal (HPA) axis, particularly through the action of neurotrophic factors like BDNF (Nature Reviews Neuroscience, 2018). Drugs exhibiting antidepressive activity—such as SSRIs, SNRIs, and NMDA receptor antagonists—interact with specific molecular targets (e.g., SLC6A4, GRIN1) to achieve this systemic effect. Because 'Antidepressive activity' describes a phenotypic result rather than a specific biological entity, it is classified as a pharmacological action rather than a therapeutic target.

Other names

Antidepressant effectThymoleptic activityAntidepressant-like activityMood-elevating effect

Modulation of monoaminergic neurotransmission (serotonin, norepinephrine, dopamine), inhibition of reuptake transporters, inhibition of monoamine oxidase, and modulation of glutamatergic signaling and neurotrophic factors like BDNF.